Atezolizumab
Colorectal Adenocarcinoma
Arbele Pty Ltdmonoclonal_antibodyPhase 3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 73/ 100
Competitive context
49 Active assets in the Colorectal Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Calcium folinate pentahydrate Centre Hospitalier Universitaire Dijon | Phase 3 | BB |
Eloxatin Pfizer | Phase 3 | BB |
Cetuximab Bayer | Phase 2 | BB |
FLUOROURACILUM Centre Hospitalier Universitaire Dijon | Phase 3 | BB |
(+)-VINCRISTINE Pfizer | Phase 3 | B |
View all 50 →
Same molecule, other indications
Atezolizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →